LY2886721
≥99%
- Product Code: 202272
CAS:
1262036-50-9
| Molecular Weight: | 390.41 g./mol | Molecular Formula: | C₁₈H₁₆F₂N₄O₂S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
LY2886721 is a potent and selective inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which plays a key role in the production of amyloid-beta peptides. These peptides are central to the formation of amyloid plaques found in the brains of Alzheimer’s disease patients. By inhibiting BACE1, LY2886721 reduces the generation of amyloid-beta, making it a candidate for disease-modifying therapy in early-stage Alzheimer’s disease.
The compound was investigated in clinical trials to evaluate its safety, pharmacokinetics, and ability to lower amyloid-beta levels in cerebrospinal fluid. Although development was discontinued due to safety concerns observed in later stages, LY2886721 contributed valuable data on BACE1 inhibition as a therapeutic strategy. It helped validate BACE1 as a pharmacological target and informed the design of future Alzheimer’s treatments aimed at reducing amyloid burden in the brain.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | ฿7,180.00 |
+
-
|
| 10mg | 10-20 days | ฿12,220.00 |
+
-
|
LY2886721
LY2886721 is a potent and selective inhibitor of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which plays a key role in the production of amyloid-beta peptides. These peptides are central to the formation of amyloid plaques found in the brains of Alzheimer’s disease patients. By inhibiting BACE1, LY2886721 reduces the generation of amyloid-beta, making it a candidate for disease-modifying therapy in early-stage Alzheimer’s disease.
The compound was investigated in clinical trials to evaluate its safety, pharmacokinetics, and ability to lower amyloid-beta levels in cerebrospinal fluid. Although development was discontinued due to safety concerns observed in later stages, LY2886721 contributed valuable data on BACE1 inhibition as a therapeutic strategy. It helped validate BACE1 as a pharmacological target and informed the design of future Alzheimer’s treatments aimed at reducing amyloid burden in the brain.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :